News | Contrast Media | August 02, 2022

Bracco Diagnostics Inc. has announced that the U.S. Food and Drug Administration (FDA) granted import discretion of Iomeron (iomeprol injection) into the U.S. to address the ongoing iodinated contrast media shortage. The product addresses the need for the most advanced diagnostic imaging standards and will be temporarily available in the U.S. market starting at the end of August, 2022.

Bracco Diagnostics has announced that the U.S. Food and Drug Administration (FDA) granted import discretion of Iomeron® (iomeprol injection) into the U.S. to address the ongoing iodinated contrast media shortage.

Photo credit: Getty Images


August 2, 2022 – A new update has been announced as the radiology world continues to address supply disruptions of contrast media.

Bracco Diagnostics Inc., a U.S. subsidiary of Bracco Imaging S.p.A. has announced that the U.S. Food and Drug Administration (FDA) granted import discretion of Iomeron (iomeprol injection) into the U.S. to address the ongoing iodinated contrast media shortage, according to a news release issued by the company July 27, from its headquarters in Milan, Italy.

Iomeron (iomeprol injection) is a nonionic iodinated contrast medium for intravascular use in adults in various imaging procedures. Currently registered in over 50 countries in Europe and Asia, it is not approved for use in the United States.

The product addresses the need for the most advanced diagnostic imaging standards and will be temporarily available in the U.S. market starting at the end of August, 2022. It is manufactured at two Bracco locations: BIPSO GmbH, Singen (Germany), and Patheon Italia S.p.A., Ferentino (Italy).

The company offered detailed information on the temporary importation, including Importation Discretion Documentation and a Letter to Healthcare Professionals.

“We are proud that the company has worked proactively with the FDA to address the shortage of iodinated contrast agents in the U.S. market,” said Jeff Fleming, Chief Executive Officer, Bracco Diagnostics Inc. “Throughout its 95-year history, Bracco has always put people and innovation at the core of its business, and focused ongoing attention on patient health, safety, and quality of care,” added Fleming.

The temporary importation being allowed by the FDA addresses shortages of GE Healthcare’s Omnipaque (iohexol injection) and Visipaque (iodixanol injection), and Bayer’s Ultravist (iopromide injection) which resulted from COVID-19 related supply disruptions. 

Related coverage on the contrast media shortage can be found here:

https://www.itnonline.com/content/global-contrast-media-shortage-strate…

https://www.itnonline.com/content/global-contrast-media-shortage-means-…


Related Content

News | Breast Imaging

Aug. 13, 2026 – Perimeter Medical Imaging AI recently announced that Intermountain Health, the largest nonprofit health ...

Time August 14, 2026
arrow
News | Cardiac Imaging

Aug. 11, 2026 — Bracco Imaging recently announced that VueJect, its dedicated ultrasound contrast delivery system ...

Time August 12, 2026
arrow
News | Lung Imaging

Aug. 11, 2026 — Noah Medical has launched the Galaxy II software, the next evolution of its robotic-assisted ...

Time August 10, 2026
arrow
News | Radiology Business

Aug. 4, 2026 — Canon Medical Systems USA (CMSU) has appointed Tsuneo "Neo" Imai as president and chief executive officer ...

Time August 10, 2026
arrow
News | Radiology Imaging

June 15, 2026 — Lead Glass Pro, a supplier of radiation shielding products, has expanded its turnkey installation ...

Time June 18, 2026
arrow
News | Contrast Agents

June 15, 2026 – Bayer has announced that the U.S. Food and Drug Administration (FDA) approved Ambelvist (gadoquatrane) ...

Time June 16, 2026
arrow
News | Radiopharmaceuticals and Tracers

June 1, 2026 — Serac Healthcare Ltd. has presented Phase 2 data showing that SPECT-CT imaging with the radiotracer 99mTc ...

Time June 01, 2026
arrow
News | Radiology Imaging

May 18, 2026 — DICO, a company specializing in the creation of distributed diagnostic infrastructure for radiology, has ...

Time May 19, 2026
arrow
News | FDA

May 18, 2026 — ACIST Medical Systems, a Bracco company, has received U.S. Food and Drug Administration (FDA) clearance ...

Time May 18, 2026
arrow
News | X-Ray

April 29, 2026 — Results from a new study* presented at the American Roentgen Ray Society’s (ARRS) 2026 annual meeting ...

Time April 29, 2026
arrow
Subscribe Now